Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15002455 | 0.88 | AKR1C3 (0.55) | PARP1PARP2PARP3F10MAPK1 | |
| SCHEMBL16488685 | 0.87 | PARP1 (0.52) | PARP1PARP2PARP3F10 | |
| SCHEMBL15002580 | 0.84 | KDM4E (0.58) | PARP1PARP2PARP3MEN1KMT2A | |
| SCHEMBL15002410 | 0.83 | PARP1 (0.66) | PARP1PARP2PARP3 | |
| SCHEMBL15002430 | 0.81 | PARP1 (0.69) | PARP1PARP2PARP3MEN1KMT2A | |
| SCHEMBL19998330 | 0.81 | PARP1 (0.66) | PARP1PARP2PARP3 | |
| SCHEMBL17356391 | 0.79 | MAOB (0.49) | PARP1ALPLALPIALPGALDH1A1 | |
| SCHEMBL15002563 | 0.79 | PARP1 (0.69) | PARP1PARP2PARP3MEN1KMT2A | |
| SCHEMBL15002406 | 0.79 | PARP1 (0.72) | PARP1PARP2PARP3 | |
| SCHEMBL15002561 | 0.77 | PARP1 (0.64) | PARP1PARP2PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718787-B2 | Poly (ADP-ribose) polymerase inhibitor | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-08-01 | — | — | US | disclosed |
| US-20150368205-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368205-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.